← Eichor
Condition: Thyroid Eye Disease Ted Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Thyroid Eye Disease Ted

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07262476Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
NA · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07400757A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Phase 3 · 27 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07211776Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2/Phase 3 · 2 location(s) · Sling Therapeutics, Inc. · NCT06112340The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO
Phase 4 · 2 location(s) · Shanghai Changzheng Hospital · NCT07152340MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07257185A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa
Phase 4 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06927375Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07547930Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152392A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Phase 1/Phase 2 · 44 location(s) · Amgen · NCT06401044Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the A
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152366A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06569758A Clinical Study of Cizutamig in Thyroid Eye Disease
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07597200Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE Nati
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT07716397
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.